{"symbol":"GILD","fiscalQuarter":"Q2-2026","reportDate":"2026-08-06","reportTime":"AMC","status":"upcoming","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q2-2026","preBrief":{"companySnapshot":"Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $163 billion, Gilead plays a significant role in the health care sector, addressing critical health challenges and advancing treatment options.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and performance, and investors will be looking for continued growth.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth is crucial for assessing the company's ability to expand its market share and sustain operations.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Gilead reported an EPS of $2.03, surpassing estimates by 7.69%. However, the stock declined by 1.64% the following day, indicating mixed market sentiment.","promises":["Focus on expanding its portfolio of antiviral therapies.","Commitment to enhancing research and development efforts.","Plans to improve patient access to its treatments."]},"wallStreetExpectations":{"summary":"Overall expectations for Gilead's upcoming earnings report are cautious, given the mixed reactions to previous earnings despite consistent EPS beats.","bullCase":"If Gilead continues its trend of beating EPS estimates and shows strong revenue growth, it could signal robust demand for its products and lead to a positive stock reaction.","bearCase":"On the other hand, if revenue growth falls short or there are concerns about future product pipelines, this could lead to negative sentiment and a decline in stock value."},"optionsSignal":{"impliedMove":"3.77%","context":"The options market is pricing in a potential move of about 3.77%, indicating that traders expect some volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+7.69%","reaction":"-1.64%"},{"quarter":"Q4-2025","epsSurprise":"+1.92%","reaction":"-2.93%"},{"quarter":"Q3-2025","epsSurprise":"+14.62%","reaction":"-0.05%"},{"quarter":"Q2-2025","epsSurprise":"+0.80%","reaction":"+0.00%"},{"quarter":"Q1-2025","epsSurprise":"+3.31%","reaction":"-0.22%"}],"pivotalQuestions":[{"question":"What will be the reported revenue growth for Gilead's key antiviral therapies?","whyItMatters":"This figure will be critical in assessing the company's market performance and future growth potential."},{"question":"How does management plan to address any potential challenges in product development?","whyItMatters":"Investors will be keen to hear about strategies to mitigate risks and ensure continued innovation."}],"thesisBreakLevels":{"bullTrigger":"A revenue growth rate of over 10% would confirm the bull case, indicating strong demand for Gilead's products.","bearTrigger":"Conversely, if revenue growth is below 5%, it would raise concerns about the company's future prospects.","context":"The market is weighing Gilead's ability to sustain growth against potential challenges in its product pipeline."},"scenarioPlaybook":{"beatAndRaise":"If Gilead beats expectations and raises guidance, history suggests the stock could see an average one-day move of around +2.7%.","inLineCautious":"If results are in line with expectations but management's commentary is cautious, the stock may react neutrally.","miss":"If Gilead misses on revenue or EPS, the stock could decline, with historical patterns suggesting an average one-day move of -0.05%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"14 of 29 (48%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +2.7% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Gilead's potential for revenue growth, particularly in its antiviral portfolio, which has shown resilience in previous quarters.","supportingPoints":["Gilead has consistently beaten EPS estimates, indicating stronger-than-expected operational performance.","Options pricing suggests a higher expected move than historical averages, indicating potential for positive surprises."],"riskToConsensus":"If revenue growth comes in below 5%, it could challenge the current optimistic outlook."},"whatToListenFor":["Any updates on the pipeline for new antiviral therapies.","Insights on market demand for existing products.","Management's perspective on competitive pressures in the biotechnology sector.","Details on research and development investments.","Any commentary on patient access initiatives."],"metaDescription":"Gilead Sciences (GILD) reports Q2 2026 earnings on August 6. Investors are watching for revenue growth and product pipeline updates."}}